acoteamine hydrochloride | acoteamine hydrochloride is jointly developed by Japan Zeria and ansteelai (Astellas), and was approved by Japan's PMDA on March 25, 2013. Zeria and ansteelai are jointly listed and sold in Japan under the trade name of Acofide®Acoteamide hydrochloride is a novel selective acetylcholinesterase (AChE) inhibitor. Acetylcholine is an important neurotransmitter that regulates gastrointestinal motility. Acoteamide improves impaired gastric motility and delayed gastric emptying by inhibiting the degradation of acetylcholine, thus improving the symptoms of functional dyspepsia. The drug is suitable for improving postprandial abdominal distension, upper abdominal fullness and premature satiety caused by functional dyspepsia. |
use | acoteamine hydrochloride trihydrate is a gastrointestinal motility therapy used to treat functional malnutrition. A tablet for the treatment of functional dyspepsia. Acoteamine hydrochloride trihydrate is a gastrointestinal prophylaxis for the treatment of functional malnutrition. Drugs for functional dyspepsia. |
pharmacological action | acoteamine hydrochloride is a new selective acetylcholinesterase (AChE) inhibitor, which can inhibit the decomposition of ACh released from parasympathetic nerve endings, increase the amount of ACh in synaptic cleft, and improve the reduction of gastric motility and gastric emptying capacity due to functional dyspepsia, and to improve postprandial fullness, abdominal distension, early satiety and many other symptoms caused by functional dyspepsia. |
biological activity | Acotiamide Hydrochloride (YM-443, Z-338) is a acotiamide hydrochloric acid form, acotiamide a peristalsis promoter. It is a new, oral active, selective AChE inhibitor. |